Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $27.00 at The Goldman Sachs Group

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target cut by The Goldman Sachs Group from $38.00 to $27.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus assumed coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, February 11th. They set a “buy” rating and a $48.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Citigroup raised their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $44.89.

Olema Pharmaceuticals Stock Down 3.1%

Shares of NASDAQ OLMA opened at $14.60 on Wednesday. The company has a quick ratio of 8.03, a current ratio of 9.95 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.00 billion, a P/E ratio of -7.85 and a beta of 1.92. Olema Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $36.26. The business has a 50-day simple moving average of $23.56 and a two-hundred day simple moving average of $18.70.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01. Research analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Shane William Charles Kovacs sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the transaction, the insider directly owned 139,727 shares in the company, valued at approximately $4,014,356.71. This represents a 41.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $28.04, for a total transaction of $2,804,000.00. Following the completion of the sale, the insider directly owned 53,997 shares in the company, valued at $1,514,075.88. This represents a 64.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 805,501 shares of company stock valued at $23,003,832 in the last 90 days. 16.36% of the stock is owned by company insiders.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. lifted its holdings in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the last quarter. Torren Management LLC bought a new position in Olema Pharmaceuticals in the fourth quarter valued at $44,000. Russell Investments Group Ltd. purchased a new stake in Olema Pharmaceuticals during the third quarter valued at about $53,000. Finally, American Century Companies Inc. purchased a new stake in Olema Pharmaceuticals during the second quarter valued at about $54,000. 91.78% of the stock is owned by institutional investors.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Major price‑target upgrades from big banks: Citigroup raised its target to $62 (buy) and JPMorgan bumped its target to $58 (overweight), signaling outsized upside relative to the current share level and supporting buy‑side interest. Benzinga
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple quarters and extended horizon upgrades (FY2026–FY2030) while keeping a Buy rating and $38 target — this reduces near‑term downside in forecasts and is a supportive fundamental datapoint. MarketBeat
• Positive Sentiment: Recent operational/clinical and earnings headlines have attracted capital: a report notes a $68.7M investor bet tied to a breast cancer drug aimed at a 2027 launch, and coverage noting the stock rallied after better‑than‑expected earnings — both draw attention from momentum and event‑driven investors. Globe and Mail American Banking News
• Neutral Sentiment: Presentation of preclinical data at AACR (palazestrant & OP‑3136) is a nearer‑term scientific catalyst; positive data would be bullish, but upcoming abstracts/presentations are binary and uncertain. Business Insider
• Neutral Sentiment: Technicals show a steep recent pullback (down ~33% in 4 weeks) and the stock is in oversold territory—this could set up a short‑term reversal if selling eases, but it also reflects volatility after the prior run. Zacks
• Neutral Sentiment: Guggenheim trimmed its target slightly (to $38) but maintained a Buy — a modest downgrade of enthusiasm rather than a reversal. Benzinga
• Negative Sentiment: Goldman Sachs cut its target from $38 to $27 (still a Buy), which reduces consensus upside and may weigh on sentiment for more cautious investors; mixed analyst signals increase short‑term volatility. Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.